Market closedNon-fractional
Coherus BioSciences/CHRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Coherus BioSciences
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
Ticker
CHRS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Redwood City, United States
Employees
249
Website
www.coherus.com
CHRS Metrics
BasicAdvanced
$181M
Market cap
-
P/E ratio
-$0.58
EPS
0.60
Beta
-
Dividend rate
Price and volume
Market cap
$181M
Beta
0.6
Financial strength
Current ratio
3.6
Quick ratio
2.916
Long term debt to equity
-371.868
Total debt to equity
-587.903
Interest coverage (TTM)
-3.75%
Management effectiveness
Return on assets (TTM)
-16.87%
Return on equity (TTM)
42.60%
Valuation
Price to revenue (TTM)
0.537
Price to book
-2.19
Price to tangible book (TTM)
-1.29
Price to free cash flow (TTM)
-1.05
Growth
Revenue change (TTM)
64.63%
Earnings per share change (TTM)
-83.38%
3-year revenue growth (CAGR)
-11.98%
3-year earnings per share growth (CAGR)
-18.29%
What the Analysts think about CHRS
Analyst Ratings
Majority rating from 10 analysts.
CHRS Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$77M
-15.85%
Net income
$103M
-229.15%
Profit margin
133.50%
-253.47%
CHRS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.38
-$0.27
-$0.62
-$0.32
-
Expected
-$0.48
-$0.27
-$0.12
-$0.24
-$0.17
Surprise
-21.60%
-1.70%
420.28%
32.34%
-
CHRS News
AllArticlesVideos
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
GlobeNewsWire·4 weeks ago
Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference
GlobeNewsWire·2 months ago
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Coherus BioSciences stock?
Coherus BioSciences (CHRS) has a market cap of $181M as of July 27, 2024.
What is the P/E ratio for Coherus BioSciences stock?
The price to earnings (P/E) ratio for Coherus BioSciences (CHRS) stock is 0 as of July 27, 2024.
Does Coherus BioSciences stock pay dividends?
No, Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Coherus BioSciences dividend payment date?
Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Coherus BioSciences?
Coherus BioSciences (CHRS) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Coherus BioSciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.